Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Cambrian history
Cambrian company history timeline
Cambrian was co-founded in 2019 by James Peyer, a PhD in stem cell biology and former co-founder and managing partner at health-focused venture capital firm Apollo Ventures, along with billionaire investor and entrepreneur Christian Angermayer.
In October 2020, Cambrian and venture capital firm H&S Ventures co-led a $29 million funding round for bacteriophage cancer therapy company Sensei Biotherapeutics.
In February 2021, Sensei Biotherapeutics began publicly trading with an IPO and raised $133 million at a valuation of $600 million.
At the time, CEO Peyer announced that the company's pipeline was expected to have 18 drug candidates by the end of 2021.
In February 2022, Cambrian announced it had licensed rights to mTOR inhibitor programs from Swiss pharmaceutical corporation Novartis.
Rate Cambrian's efforts to communicate its history to employees.
Cambrian jobs
Do you work at Cambrian?
Is Cambrian's vision a big part of strategic planning?
Cambrian competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Hotspot Therapeutics | 2017 | $660,000 | 47 | - |
| Cellular Approaches | 2016 | $36,000 | 5 | - |
| Edgewise Therapeutics | 2017 | $30,000 | 45 | 3 |
| Attralus | - | $550,000 | 30 | - |
| Outlook Therapeutics | 2011 | $8.1M | 10 | - |
| Park Place Senior Living | - | $77.0M | 50 | 1 |
| Homeward | 2018 | $1.1M | 25 | 22 |
Cambrian history FAQs
Zippia gives an in-depth look into the details of Cambrian, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Cambrian. The employee data is based on information from people who have self-reported their past or current employments at Cambrian. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Cambrian. The data presented on this page does not represent the view of Cambrian and its employees or that of Zippia.
Cambrian may also be known as or be related to Cambrian, Cambrian BioPharma and Cambrian Biopharma.